title: Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer.
abstract: Twenty to 30% of patients with non-small-cell lung cancer (NSCLC) in stage III are not resectable primarily with 5-year survival less than 10%. Since the majority of patients die from metastases, efforts have been made in the past to improve prognosis by application of neoadjuvant chemoradiotherapy regimens followed by subsequent resection. In a phase II study performed between 1993 and 1998, 93 patients in stage III (IIIA, 16%; IIIB, 84%) received an induction chemotherapy consisting of two cycles cisplatin (100 mg/m2) and vindesine (3 mg/m2) with subsequent sequential radiotherapy of 36 Gy. Sixty-five patients demonstrated partial or complete remission. Sixty underwent surgery; in 49 of them complete resection was possible. Five-year survival in the whole group was 24%, and that in the surgical cohort 39%. Six patients had no residual tumor. Postoperative N0 status was associated with a 5-year survival of 75%, and stage N1-3 with 13%. Thirty-day mortality was 7% postoperatively. Neoadjuvant chemoradiotherapy can significantly improve long-term survival in stage III NSCLC with an acceptable therapy-induced mortality.
authors.affiliation: Department of Thoracic Surgery, Klinik Schillerhöhe, Gerlingen, Germany. friedel@klinik-schillerhoehe.de
authors.forename: G
authors.initials: G
authors.lastname: Friedel
authors.forename: D
authors.initials: D
authors.lastname: Hruska
authors.forename: W
authors.initials: W
authors.lastname: Budach
authors.forename: M
authors.initials: M
authors.lastname: Wolf
authors.forename: T
authors.initials: T
authors.lastname: Kyriss
authors.forename: M
authors.initials: M
authors.lastname: Hürtgen
authors.forename: H P
authors.initials: HP
authors.lastname: Eulenbruch
authors.forename: R
authors.initials: R
authors.lastname: Dierkesmann
authors.forename: H
authors.initials: H
authors.lastname: Toomes
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D002945:Cisplatin; D014751:Vindesine